Form 4: Ionis Pharmaceuticals EVP, Finance & CFO Elizabeth L. Hougen Reports Stock Option Grant

Elizabeth L. Hougen, EVP, Finance & CFO of Ionis Pharmaceuticals, reports the grant of stock options for 31,000 shares on January 2, 2025.

Summary

• On January 3, 2025, Elizabeth L. Hougen, the EVP, Finance & CFO of Ionis Pharmaceuticals, filed a Form 4.
• The report details the grant of non-qualified stock options to Hougen on January 2, 2025.
• Hougen received options for 31,000 shares of Ionis Pharmaceuticals common stock at an exercise price of $34.69 per share.
• The options vest over a period of 4 years, with 25% vesting on January 2, 2026, and the remaining shares vesting in 36 equal monthly installments thereafter.

Sentiment

Score: 7

Explanation: The document is a routine disclosure of a stock option grant, which is generally viewed neutrally to positively as it aligns executive incentives with shareholder value.

Positives

• The grant of stock options aligns the executive's interests with those of the shareholders, incentivizing performance and value creation.

Industry Context

Stock option grants are a common practice in the pharmaceutical industry to incentivize executives and align their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotechnology and pharmaceutical industries.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their executive compensation plans.
• The vesting schedule and exercise price are generally aligned with industry norms to incentivize long-term performance.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the executive to drive company performance.
• Employees may see the grant as a sign of confidence in the company's future.

Key Dates